Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04303403 | Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma | unknown | Phase 1 | 48 | National Cancer Centre, SingaporeOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01068327 | Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer | completed | Phase 1 | 46 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03122106 | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | terminated | Phase 1 | 15 | Washington University School of MedicineOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03611556 | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | completed | Phase 1 / Phase 2 | 213 | MedImmune LLCINDUSTRY | 4 | Oct 3, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03109041 | Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source | completed | Phase 1 | 2 | CivaTech OncologyINDUSTRY | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05930119 | HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study | completed | Phase 1 | 24 | HutchmedINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT00638612 | AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)(PaTK01) | completed | Phase 1 | 27 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 15, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04050085 | SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | completed | Phase 1 | 6 | University of California, DavisOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02959164 | Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma | completed | Phase 1 | 36 | Mohammed MilhemOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT02324543 | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT01835041 | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 1 | 21 | Wake Forest University Health SciencesOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04990037 | A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma(CAPAFOUR) | completed | Phase 1 | 25 | Cantargia ABINDUSTRY | 2 | Jun 29, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02351765 | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers(ABC-08) | completed | Phase 1 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03118349 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | terminated | Phase 1 | 4 | BioNTech Research & Development, Inc.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | withdrawn | Phase 1 | 0 | University of OxfordOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT03871959 | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma(CATRIPCA) | completed | Phase 1 | 54 | Centre Leon BerardOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT04542291 | Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition | completed | Phase 1 | 15 | Washington University School of MedicineOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT02930902 | Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases(AntiCEA_CART) | terminated | Phase 1 | 2 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma(PANFIRE) | completed | Phase 1 / Phase 2 | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT04080024 | A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer(SPAGOPIX-01) | completed | Phase 1 | 14 | Spago Nanomedical ABINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05557851 | Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas | unknown | Phase 1 | 36 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | terminated | Phase 1 | 12 | Danielle Kim TurgeonOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT03883919 | Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy | completed | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02349867 | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | completed | Phase 1 | 23 | Virginia Commonwealth UniversityOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT00981162 | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride | completed | Phase 1 | 12 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02394535 | Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 11, 2023source: clinicaltrials